𝔖 Bobbio Scriptorium
✦   LIBER   ✦

LPS-induced expression of a novel chemokine receptor (L-CCR) in mouse glial cells in vitro and in vivo

✍ Scribed by Mike W. Zuurman; Joost Heeroma; Nieske Brouwer; Hendrikus W.G.M. Boddeke; Knut Biber

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
332 KB
Volume
41
Category
Article
ISSN
0894-1491

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

There is increasing evidence that chemokines, specialized regulators of the peripheral immune system, are also involved in the physiology and pathology of the CNS. It is known that glial cells (astrocytes and microglia) express various chemokine receptors like CCR1, ‐3, ‐5, and CXCR4. We have investigated the possible expression of the known CC chemokine receptors (CCR1–8 and D6) in murine glial cells. In addition, we examined possible glial expression of the orphan CC chemokine receptor L‐CCR that has been identified previously in murine macrophages. We report here expression of L‐CCR mRNA in murine astrocytes and microglia. Furthermore, L‐CCR mRNA expression was strongly induced after application of bacterial lipopolysaccharide (LPS), both in vitro and in vivo. Functional studies and binding experiments using biotinylated monocyte chemoattractant protein (MCP)‐1 (CCL2) indicate that CCL2 could be a candidate chemokine ligand for glial L‐CCR. Based on the data presented, it is suggested that L‐CCR is a functional glial chemokine receptor that is important in neuroimmunology. GLIA 41:327–336, 2003. Β© 2003 Wiley‐Liss, Inc.

πŸ“œ SIMILAR VOLUMES

In vitro and in vivo prevention of HIV p
In vitro and in vivo prevention of HIV protease inhibitor-induced insulin resistance by a novel small molecule insulin receptor activator
✍ Mingshan Cheng; Seiyu Chen; Steven R. Schow; Vara Prasad Manchem; Wayne R. Speva πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 264 KB

## Abstract Protease inhibitor (PI) therapy for the treatment of patients infected with human immunodeficiency virus is frequently associated with insulin resistance and diabetic complications. These adverse effects of PI treatment result to a large extent from their inhibition of insulin‐stimulate

Increased expression of the mannose 6-ph
Increased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo
✍ Jason S. Lee; Jocelyn Weiss; Janet L. Martin; Carolyn D. Scott πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 French βš– 302 KB πŸ‘ 2 views

The mannose 6-phosphate/insulin-like growth factor-II receptor (M6P/IGF-IIR) is thought to act as a suppressor of tumor growth by binding the mitogenic peptide IGF-II and modulating its extracellular levels via degradation. This receptor has been found to be absent or nonfunctional in a high proport

A novel NF-ΞΊB inhibitor DHMEQ selectivel
A novel NF-ΞΊB inhibitor DHMEQ selectively targets constitutive NF-ΞΊB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo
✍ Mariko Watanabe; Md. Zahidunnabi Dewan; Takamitu Okamura; Masataka Sasaki; Kinji πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 French βš– 453 KB

Multiple myeloma (MM) is a fatal lymphoid malignancy that is incurable with conventional modalities of chemotherapy. Strong and constitutive activation of nuclear factor kappa B (NF-kappaB) is a common characteristic of MM cells. In our study we successfully target NF-kappaB with a novel NF-kappaB i